Rein Therapeutics Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James Brian Windsor
- Full Time Employees
- 10
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 12407 N. Mopac Expy. Austin TX United States of America 78758
- IPO Date
- Jun 29, 2017
- CIK
- 0001420565
- Website
- reintx.com
- Similar Companies
- Business
- Rein Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan pulmonary and fibrosis indications. The company’s core products include LTI-03, a novel synthetic peptide designed to treat idiopathic pulmonary fibrosis (IPF) by promoting alveolar epithelial cell survival and inhibiting profibrotic signaling; LTI-01, a proenzyme with completed Phase 1b and Phase 2a trials for loculated pleural effusions; and a pipeline of preclinical programs targeting cystic fibrosis and systemic fibrosis, including a peptide program focused on caveolin-1 protein and LTI-05, an epithelial sodium channel therapy. Rein Therapeutics primarily operates in the United States and internationally through clinical trial sites in the United Kingdom, Germany, Poland, and Australia. The company was founded in 2001 and is headquartered in Austin, Texas. Recent major developments include the lifting of the U.S. FDA's full clinical hold on Rein's Phase 2 RENEW trial of LTI-03 for IPF, enabling the company to resume enrollment across approximately 20 U.S. sites in late 2025 or early 2026, complementing about 30 global sites. Early data from the ongoing trial suggest that LTI-03 may slow fibrosis and support lung repair. The company has also secured European Medicines Agency (EMA) authorization in October 2025 to initiate its global Phase 2 trial program, including sites in Germany and Poland. Additionally, Rein entered into strategic financing agreements in mid-2025 providing potential access to up to $21 million in capital to support the advancement of its clinical programs. A collaboration with Qureight Ltd. has been announced to integrate deep-learning platforms into Rein’s Phase 2 clinical trial, reflecting a strategic use of technology to enhance trial outcomes. Rein operates within the biotechnology sector, addressing significant unmet medical needs in rare and orphan disease markets, targeting patient populations with pulmonary fibrosis, pleural effusions, and cystic fibrosis. The company evolved from Aileron Therapeutics, Inc., renaming to Rein Therapeutics Inc. in 2007. Its pipeline and clinical activities underscore a commitment to developing transformative therapies for underserved pulmonary diseases with global clinical operations and financial strategies to advance its innovative drug candidates. The company is led by CEO James Windsor and maintains its clinical development focus on orphan and rare disease indications.
All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics (NASDAQ:RNTX) Stock Price Up 1.6% – What’s Next?
Rein Therapeutics (NASDAQ:RNTX) Shares Down 0.8% – Here’s Why
Why Is Rein Therapeutics Stock Trading Higher On Monday?
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders
US FDA puts on hold Rein Therapeutics' lung disease drug trial
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025